Synlogic to develop novel living medicines, now provided an overview of recent progress and outlined key objectives and anticipated milestones for 2018. SYNB1020: An orally delivered, first-in-class, Synthetic Biotic medicine designed for treatment of elevated blood ammonia levels (hyperammonemia) in genetic urea cycle disorders (UCDs) or in chronic liver disease. Plan to present full data from Synlogic’s first-in-human clinical study evaluating SYNB1020 in healthy volunteers at two medical meetings in the first quarter of 2018: Society for Inherited Metabolic Disorders (SIMD) Annual Meeting – March 11-14, 2018, in San Diego, CA. International Conference on Ureagenesis Defects: Novel Models and Treatment Options – March 19-21, 2018, in Engadin, Switzerland. Initiation of Phase 1b/2a study in cirrhotic patients with elevated ammonia in the first quarter of 2018, with interim data expected by year-end. An Investigational New Drug (IND) application has been cleared by the U.S. Food and Drug Administration (FDA) enabling Synlogic to initiate this clinical trial. Initiation of second Phase 1b/2a study in UCD patients in mid-2018, with data expected in 2019. SYNB1618: An orally delivered, Synthetic Biotic medicine designed for the treatment of phenylketonuria (PKU) Initiation of Phase 1 SAD/MAD study in healthy volunteers and PKU patients in the first half of 2018, with interim data expected in the second half of 2018. Pre-clinical data and early pipeline programs Additional data to be presented at major scientific and medical meetings throughout the year demonstrating the breadth of Synlogic’s Synthetic Biotic platform in new indications, including datafrom the company’s research and preclinical immuno-oncology program. Corporate Advancement of collaborations with AbbVie in inflammatory bowel disease (IBD) and Ginkgo in neurological and liver disease. Continued exploration of additional strategic opportunities to expand the platform’s reach.
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. It designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Companyâs preclinical work includes additional metabolic disease research.
SYNLOGIC, INC. 
